Comparison of 6-18F-fluorodopamine PET with 123I- metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages 1613-1619

  Ilias, Ioannis ^a   Chen, Clara C ^b   Carrasquillo, Jorge A ^b   Whatley, Millie ^b   Ling, Alexander ^b   Lazúrová, Ivica ^c   Adams, Karen T ^a   Perera, Shiromi ^a   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

111In pentetreotide; 123I metaiodobenzylguanidine; 18F fluorodopamine; Pheochromocytoma; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; (3 IODOBENZYL)GUANIDINE; 6 FLUORODOPAMINE; 6-FLUORODOPAMINE; DIAGNOSTIC AGENT; DOPAMINE; DRUG DERIVATIVE; FLUORINE; INDIUM; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHEMICAL ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; DIAGNOSTIC IMAGING; METASTASIS; METHODOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; DIAGNOSTIC IMAGING; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 53749086628     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.052373     Document Type: Article

References (50)

1. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med. 1999;43:217-223.
2. Nielsen JT, Nielsen BV, Rehling M. Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT. Clin Nucl Med. 1996;21:695-699.
3. 131I]- metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;6:119-124.
4. 111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
5. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53. Oxford, U.K.: Pergamon Press; 1988:329-331.
6. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
7. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269.
8. 123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun. 2006;27:31-36.
9. 11C hydroxyephedrine PET. Radiology. 2004;230:423-428.
10. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125-1131.
11. Shulkin BL, Wienland DM, Shapiro B, Sisson JC. PET epinephrine studies of pheochromocytoma [abstract]. J Nucl Med. 1995;36(suppl):229P.
12. 18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13: 187-197.
13. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-694.
14. 18F DOPA whole-body PET-initial results. Radiology. 2002;222:507-512.
15. 18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6-8.
16. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003; 88:4083-4087.
17. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004; 89:479-491.
18. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1-6.
19. Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes. 1998;106:373-376.
20. Ueberberg B, Tourne H, Redman A, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res. 2005;37:722-728.
21. Unger N, Serdiuk I, Sheu SY, et al. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocr Res. 2004;30:931-934.
22. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20: 716-731.
23. Lauriero F, Rubini G, D'Addabo F, Rubini D, Schettini F, D'Addabo A. I-131 MIBG scintigraphy of neuroectodermal tumors: comparison between I-131 MIBG and In-DTPA-octreotide. Clin Nucl Med. 1995;20:243-249.
24. Limouris GS, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scintimaging in neural crest tumors. Anticancer Res. 1997;17:1589-1592.
25. Lastoria S, Maurea S, Vergara E, et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med. 1995; 39:145-149.
26. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434-440.
27. Duet M, Sauvaget E, Petelle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767-1774.
28. 111In octreotide scintigraphy in the evaluation of head and neck lesions. AJNR. 1997;18:1073-1080.
29. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895-902.
30. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340:1872-1879.
31. Lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123:101-109.
32. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568-580.
33. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin Nucl Med. 2005;30:579-581.
34. Shirkare S, Kuwert T, Weckesser M, Czech N, Langen KJ, Muller-Gartner HW. Localization of a pheochromocytoma using I-123 MIBG adrenal scintigraphy. J Postgrad Med. 1994;40:85-87.
35. Bravo EL. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr Rev. 1994;15:356-358.
36. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999;142:619-624.
37. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imaging in patients with paragangliomas: computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med. 1996;40:365-371.
38. Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med. 1995;39(4, suppl 1):S3-S8.
39. Schmedtje JFJ, Sax S, Pool JL, Goldfarb RA, Nelson EB. Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am J Med. 1987;83: 770-772.
40. 18F-labelled deoxyglucose. Eur J Surg. 2001;167:866-870.
41. 11C-hydroxyephedrine-PET [abstract]. Radiology. 2002;225(suppl):S425.
42. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-329.
43. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab. 2001;86:3641-3646.
44. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4:61-68.
45. Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med. 2000;25:440-442.
46. 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27:583-587.
47. Cecchin D, Lumachi F, Marzola MC, et al. A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer. 2006;13:525-533.
48. van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine. 2003;20:307-311.
49. Breeman WA, De Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1412-1429.
50. 18F-fluorodopamine PET. J Nucl Med. 2007;48: 1940-1944.